LPSN · As filed with the SEC
Liveperson cash flow statement, by fiscal year
The statement as Liveperson presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| OPERATING ACTIVITIES: | ||||||||
| Net loss | (67,233) | (134,273) | (100,435) | (225,747) | (124,974) | (107,594) | (96,071) | (25,032) |
| WildHealth | — | — | — | (23,400) | — | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation expense | 14,256 | 21,989 | 11,854 | 109,638 | 69,656 | 65,946 | 44,105 | 14,841 |
| Depreciation | — | 30,310 | 32,557 | 32,284 | 27,423 | 22,826 | 16,366 | — |
| Loss on disposal | — | — | — | 0 | 0 | 5,147 | — | — |
| Amortization of tenant allowance | — | — | — | — | 0 | 0 | (516) | (326) |
| Amortization of purchased intangibles | — | — | — | — | — | — | — | 2,813 |
| Amortization of purchased intangibles | — | — | — | — | — | — | 2,932 | — |
| Depreciation and amortization | 21,975 | — | — | — | — | — | — | 14,188 |
| Impairment on investments | — | — | — | — | — | — | — | 0 |
| Reduction of operating lease right-of-use assets | 17 | 4,059 | — | — | — | — | — | — |
| Amortization of purchased intangible assets and finance leases | 757 | 11,962 | 22,196 | 22,112 | 5,609 | 3,552 | — | — |
| Amortization of finance leases | — | — | — | — | 3,718 | — | — | — |
| Amortization of debt issuance costs and accretion of debt discount | 7,614 | 4,513 | 4,043 | 3,778 | 2,499 | 1,340 | 956 | — |
| Accretion of debt discount on convertible senior notes | — | — | 0 | 0 | 33,309 | 11,564 | 7,605 | — |
| Impairment of goodwill | 41,595 | 60,551 | 11,895 | — | — | — | — | — |
| Impairment of intangibles and other assets | 2,108 | 46,872 | 7,974 | — | — | — | — | — |
| Change in fair value of Warrants | (13,202) | 12,232 | — | — | — | — | — | — |
| Change in fair value of contingent consideration | 0 | 0 | 4,629 | (8,516) | 0 | (263) | (328) | — |
| Gain on troubled debt restructuring | (42,429) | — | — | — | — | — | — | — |
| Gain on debt extinguishment | 0 | (73,083) | (7,200) | — | — | — | — | — |
| Paid-in-Kind Interest | 15,263 | 5,810 | — | — | — | — | — | — |
| Allowance for credit losses | 866 | 14,959 | 3,319 | 5,644 | 4,879 | 3,211 | 2,159 | 1,788 |
| Deferred income taxes | — | — | — | — | — | — | — | (309) |
| Loss (gain) on divestiture | 0 | 558 | (17,591) | — | — | — | — | — |
| Gain on settlement of leases | — | 0 | 0 | (242) | (3,483) | — | — | — |
| Deferred income taxes | 622 | 623 | 1,046 | (1,161) | (6,239) | 579 | (1,207) | — |
| Equity loss in joint venture | 0 | 0 | 2,264 | — | — | — | — | — |
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 1,160 | 37,548 | 1,457 | (38) | (17,309) | 6,371 | (43,757) | (9,662) |
| Prepaid expenses and other current assets | 3,591 | 7,300 | (3,411) | (5,979) | (3,178) | 23 | (4,712) | (14,628) |
| Contract acquisition costs | 10,383 | 3,331 | 4,992 | (6,370) | (1,876) | (6,463) | (13,718) | — |
| Other assets | 34 | 652 | 1,361 | (153) | 547 | (37) | (30) | (107) |
| Accounts payable | — | — | (13,570) | 12,050 | 801 | (733) | 3,808 | 2,199 |
| Accounts payable, accrued expenses and other current liabilities | (19,823) | (44,518) | 24,343 | 7,485 | 8,626 | 22,931 | (10,882) | (205) |
| Deferred revenue | — | — | — | — | — | — | — | 19,005 |
| Deferred revenue | (4,315) | (23,058) | (3,169) | (12,341) | 7,774 | (3,118) | 33,953 | — |
| Decrease in net operating lease asset and liability | — | — | — | — | — | 8,276 | 388 | — |
| Deferred tax liability | — | — | — | — | — | 0 | — | — |
| Operating lease liabilities | (14) | (4,868) | (523) | (2,638) | (4,590) | — | — | — |
| Other liabilities | (3,660) | 1,401 | (7,796) | 8,093 | 55 | 47 | (209) | 214 |
| Net cash used in operating activities | (30,435) | (15,130) | (19,765) | (62,101) | 3,247 | 33,605 | (59,158) | 4,779 |
| INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment, including capitalized software | — | — | — | — | — | — | (47,582) | (21,938) |
| Payments for acquisitions and intangible assets, net of cash acquired | — | — | — | — | — | — | (924) | (7,286) |
| Purchases of property and equipment, including capitalized internal-use software development costs | (12,088) | (25,142) | (28,657) | (48,486) | (45,703) | (41,641) | — | — |
| Proceeds from divestiture | 0 | 0 | 13,819 | — | — | — | — | — |
| Payments for acquisitions, net of cash acquired | — | 0 | 0 | (3,430) | (70,759) | — | — | — |
| Purchases of intangible assets | (1,639) | (3,074) | (4,004) | (2,680) | (2,610) | (1,835) | — | — |
| Cash held as collateral | — | — | — | — | — | 0 | 0 | 1,451 |
| Repayment of debt acquired in acquisition | — | — | 0 | 0 | (21,177) | — | — | — |
| Investment in joint venture | — | 0 | 0 | (2,264) | — | — | — | — |
| Net cash used in investing activities | (13,727) | (28,216) | (18,842) | (56,860) | (140,249) | (43,476) | (48,506) | (27,773) |
| FINANCING ACTIVITIES: | ||||||||
| Payment on settlement of warrants | (1,297) | — | — | — | — | — | — | — |
| Payment in connection with troubled debt restructuring | (45,000) | — | — | — | — | — | — | — |
| Proceeds from issuance of 2029 convertible senior notes | 0 | 100,000 | — | 0 | (4) | 517,500 | 230,000 | — |
| 2024 Notes | 0 | (72,492) | — | — | — | — | — | — |
| 2026 Notes | 0 | (4,901) | — | — | — | — | — | — |
| Payment of debt issuance costs | 0 | (7,584) | (149,702) | 0 | 0 | (11,800) | (8,635) | — |
| Payment related to contingent consideration | — | — | — | — | 0 | 0 | (487) | — |
| Purchase of capped call option | — | — | — | 0 | 0 | (46,058) | (23,184) | — |
| Principal payments for finance leases | (26) | (401) | (3,330) | (3,734) | (3,554) | (1,154) | — | — |
| Proceeds from issuance of common stock in connection with the exercise of options and ESPP | 820 | 350 | 1,890 | 5,573 | 16,110 | 25,355 | 21,060 | 35,271 |
| Repurchase of common stock | — | 0 | 0 | (221) | (709) | 0 | (903) | (1,345) |
| Net cash (used in) provided by financing activities | (45,503) | 14,972 | (151,142) | 1,618 | 11,843 | 483,843 | 217,851 | 33,926 |
| EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | — | — | — | — | — | — | — | (598) |
| CHANGE IN CASH AND CASH EQUIVALENTS | — | — | — | — | — | — | — | 10,334 |
| CASH AND CASH EQUIVALENTS - Beginning of the year | — | — | — | — | — | — | 66,449 | 56,115 |
| CASH AND CASH EQUIVALENTS - End of the year | — | — | — | — | — | — | — | 66,449 |
| Effect of foreign exchange rate changes on cash and cash equivalents | 1,432 | (1,314) | 465 | (3,981) | (5,461) | 3,657 | (113) | — |
| Net decrease in cash, cash equivalents, and restricted cash | (88,233) | (29,688) | (189,284) | (121,324) | (130,620) | 477,629 | 110,074 | — |
| Cash, cash equivalents, and restricted cash - beginning of year | 183,237 | 212,925 | 392,198 | 523,532 | 654,152 | 176,523 | 66,449 | — |
| Cash, cash equivalents, and restricted cash - end of year | 95,004 | 183,237 | 212,925 | 392,197 | 523,532 | 654,152 | 176,523 | — |
| Supplemental disclosure of other cash flow information: | ||||||||
| Cash paid for income taxes, net | 1,207 | 1,886 | 1,858 | 3,237 | 582 | 4,651 | 3,304 | 5,144 |
| Cash paid for interest | 9,220 | 3,710 | 1,235 | 1,932 | 2,090 | 1,931 | — | — |
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Issuance of Second Lien Notes due 2029 in connection with troubled debt restructuring | 115,000 | 0 | 0 | (159,407) | — | — | — | — |
| Issuance of preferred stock in connection with troubled debt restructuring | 20,664 | — | — | — | — | — | — | — |
| Issuance of common stock in connection with troubled debt restructuring | 49,380 | — | — | — | — | — | — | — |
| e-bot7 | — | — | 0 | 0 | — | — | — | — |
| Tenfold | — | — | 0 | 0 | — | — | — | — |
| VoiceBase | — | — | 0 | — | — | — | — | — |
| WildHealth | — | 0 | 0 | 17,675 | — | — | — | — |
| e-bot7 | — | 0 | 0 | 7,362,000 | — | — | — | — |
| Tenfold | — | 0 | 0 | 6,558,000 | — | — | — | — |
| VoiceBase | — | 0 | 0 | 16,067,000 | — | — | — | — |
| WildHealth | — | 0 | 0 | 42,234,000 | — | — | — | — |
| Purchase of property and equipment and intangible assets in accounts payable | 264 | 1,093 | 2,088 | 1,022 | 470 | 1,638 | 1,198 | 190 |
| Leasehold improvements funded by landlord | — | — | — | — | — | 0 | 0 | 1,551 |
| Right-of-use assets obtained in exchange for operating lease liabilities | 0 | 100 | 5,198 | 0 | 2,125 | 0 | 21,588 | — |
| Right of use assets obtained in exchange for finance lease liabilities | — | — | — | — | — | 10,818 | (19,467) | — |
| Right-of-use assets obtained in exchange for finance lease liabilities | 0 | 0 | 3,693 | 0 | 0 | — | — | — |
| Conversable Dec 13 2019 | — | — | — | — | 0 | 0 | 1,000 | — |
| BotCentral | — | — | — | — | — | 0 | 0 | 1,000 |
| Conversable | — | — | — | — | — | — | — | 2,850 |
| Conversable Sep 27 2018 | — | — | — | — | — | 0 | 0 | — |
| AdvantageTec | — | — | — | — | — | 0 | 0 | 4,300 |
| e-bot7 | — | — | — | — | 20,012 | — | — | — |
| Tenfold | — | — | — | — | 41,224 | — | — | — |
| VoiceBase | — | — | — | — | 67,557 | — | — | — |
| Issuance of common shares as earn-out payment associated with business acquisitions | — | — | — | — | — | 293 | — | — |
| AdvantageTec | — | — | — | 0 | 0 | 293 | — | — |
| Issuance of shares of common stock as earn-out payment in connection with AdvantageTec Inc. (in shares) | — | — | — | — | — | 11,508 | — | — |
| Issuance of shares of common stock to settle cash awards | — | 0 | 0 | 17,300 | 33,503 | 24,657 | — | — |
| Issuance of shares of common stock to settle cash awards (in shares) | — | — | — | — | 400,700 | 991,905 | — | — |
| e-bot7 | — | — | — | — | 6,170 | — | — | — |
| Tenfold | — | — | — | — | 6,946 | — | — | — |
| VoiceBase | — | — | — | — | 16,714 | — | — | — |
| Conversable Dec 13 2019 | — | — | — | — | — | — | 38,462 | — |
| BotCentral | — | — | — | — | — | — | — | 85,861,000 |
| Conversable | — | — | — | — | — | — | — | 115,385,000 |
| AdvantageTec | — | — | — | — | — | — | — | 117,082,000 |
| Conversable Inc | — | — | — | — | — | 0 | 0 | 1,496 |
| AdvantageTec | — | — | — | — | — | 0 | 0 | 876 |
| e-bot7 | — | — | — | 351,462 | 351,462 | — | — | — |
| WildHealth | — | — | — | 776,825,000 | — | — | — | — |
| Tenfold | — | — | — | — | 698,219 | — | — | — |
| VoiceBase | — | — | — | — | 1,080,532 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.